2. Membrane Transporter/Ion Channel Neuronal Signaling
  3. iGluR
  4. DL-AP5

DL-AP5  (Synonyms: 2-APV; DL-2-Amino-5-phosphonovaleric acid)

Cat. No.: HY-100714 Purity: ≥98.0%
SDS COA Handling Instructions

Molarity Calculator

DL-AP5 (2-APV) is a competitive NMDA (N-methyl-D-aspartate) receptor antagonist. DL-AP5 shows significantly antinociceptive activity. DL-AP5 specifically blocks on channels in the rabbit retina.

For research use only. We do not sell to patients.

DL-AP5 Chemical Structure

DL-AP5 Chemical Structure

CAS No. : 76326-31-3

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in Water
ready for reconstitution
 USD 55 In-stock
Solution
10 mM * 1 mL in Water USD 55 In-stock
Solid
5 mg USD 50 In-stock
10 mg USD 88 In-stock
25 mg USD 194 In-stock
50 mg USD 331 In-stock
100 mg USD 550 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of DL-AP5:

DL-AP5 Related Antibodies

Top Publications Citing Use of Products

View All iGluR Isoform Specific Products:

View All Isoforms
AMPA Receptor NMDA Receptor Kainate Receptor

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

DL-AP5 (2-APV) is a competitive NMDA (N-methyl-D-aspartate) receptor antagonist. DL-AP5 shows significantly antinociceptive activity. DL-AP5 specifically blocks on channels in the rabbit retina[1][2][3].

IC50 & Target

NMDA Receptor

 

Cellular Effect
Cell Line Type Value Description References
Pyramidal neuron IC50
0.31 μM
Compound: L-AP5
sensitization of CA1 pyramidal neurons by 2 to depolarizations by L-AP4,L-AP5 and L-AP6 after exposure to quisqualic acid
sensitization of CA1 pyramidal neurons by 2 to depolarizations by L-AP4,L-AP5 and L-AP6 after exposure to quisqualic acid
[PMID: 7966155]
Pyramidal neuron IC50
2.2 μM
Compound: L-AP5
sensitization of CA1 pyramidal neurons by 2 to depolarizations by L-AP4, L-AP5 and L-AP6 after reversal with L-alpha-AA
sensitization of CA1 pyramidal neurons by 2 to depolarizations by L-AP4, L-AP5 and L-AP6 after reversal with L-alpha-AA
[PMID: 7966155]
Pyramidal neuron IC50
2.3 μM
Compound: L-AP5
sensitization of CA1 pyramidal neurons by 2 to depolarizations by L-AP4, L-AP5 and L-AP6 before exposure to quisqualic acid
sensitization of CA1 pyramidal neurons by 2 to depolarizations by L-AP4, L-AP5 and L-AP6 before exposure to quisqualic acid
[PMID: 7966155]
In Vitro

DL-AP5 (100 μM) partially prevents glutamate-induced increase in Arc/Arg3.1 protein levels[5].
DL-AP5 decreases the NMDA-induced Arc/Arg3.1 upregulation[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

DL-AP5 Related Antibodies
In Vivo

DL-AP5 (0-10 μg/rat, Intra-CA1) significantly decreases the effect of NMDA[3].
DL-AP5 (0-10 nmol, Intracerebroventricular injection) causes a dose-dependent increase in food consumption[4].
DL-AP5 (5 nmol, Intracerebroventricular injection) attenuates the decreased food consumption induced by the intracerebroventricular injection of ghrelin[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male Wistar rats (180-230 g)[3]
Dosage: 1, 3.2 and 10 μg/rat
Administration: Injected into the intra-dorsal hippocampal (intra-CA1) immediately after shock administration, once
Result: Significantly decreased the effect of NMDA (10-2 μg/rat, intra-CA1) with significant interaction.
Animal Model: Broilers cockerels (3-h fooddeprived (FD3), n=8 for each group)[4]
Dosage: 0, 2.5, 5, and 10 nmol; in a volume of 10 μL
Administration: Intracerebroventricular injection
Result: Caused a dose-dependent increase in food consumption which was significant for 5 and 10 nmol doses.
Animal Model: Broilers cockerels (3-h fooddeprived (FD3), n=8 for each group)[4]
Dosage: 5 nmol
Administration: Intracerebroventricular injection, followed by ghrelin (0.6 nmol)
Result: Attenuated the decreased food consumption induced by the intracerebroventricular injection of ghrelin.
Molecular Weight

197.13

Formula

C5H12NO5P
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

NC(CCCP(O)(O)=O)C(O)=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

H2O : 33.33 mg/mL (169.08 mM; ultrasonic and warming and heat to 60°C)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 5.0728 mL 25.3640 mL 50.7279 mL
5 mM 1.0146 mL 5.0728 mL 10.1456 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  PBS

    Solubility: 50 mg/mL (253.64 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
Purity & Documentation

Purity: ≥98.0%

SDS (393 KB)

COA (245 KB) HNMR (236 KB) CNMR (287 KB) MS (71 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
H2O 1 mM 5.0728 mL 25.3640 mL 50.7279 mL 126.8199 mL
5 mM 1.0146 mL 5.0728 mL 10.1456 mL 25.3640 mL
10 mM 0.5073 mL 2.5364 mL 5.0728 mL 12.6820 mL
15 mM 0.3382 mL 1.6909 mL 3.3819 mL 8.4547 mL
20 mM 0.2536 mL 1.2682 mL 2.5364 mL 6.3410 mL
25 mM 0.2029 mL 1.0146 mL 2.0291 mL 5.0728 mL
30 mM 0.1691 mL 0.8455 mL 1.6909 mL 4.2273 mL
40 mM 0.1268 mL 0.6341 mL 1.2682 mL 3.1705 mL
50 mM 0.1015 mL 0.5073 mL 1.0146 mL 2.5364 mL
60 mM 0.0845 mL 0.4227 mL 0.8455 mL 2.1137 mL
80 mM 0.0634 mL 0.3170 mL 0.6341 mL 1.5852 mL
100 mM 0.0507 mL 0.2536 mL 0.5073 mL 1.2682 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

DL-AP5 Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

DL-AP576326-31-32-APV DL-2-Amino-5-phosphonovaleric acidiGluRIonotropic glutamate receptorsAntinociceptive activityTonic painGanglion cellsRetinaArc/Arg3.1Glutamate receptorInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
DL-AP5
Cat. No.:
HY-100714
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.